Results 121 to 130 of about 38,476 (212)

Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report

International Journal of Emergency Medicine
Dabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli, Olivier Pantet, Julien Castioni, Nima Vakilzadeh, Lorenzo Alberio, Olivier Hugli   +5 more
doaj   +1 more source

Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study [PDF]

, 2015
BACKGROUND & AIMS: Use of dabigatran, an inhibitor of thrombin, increases the risk of gastrointestinal bleeding (GIB). However, it is not clear whether gastroprotective agents (GPAs) prevent GIB in dabigatran users.
Chan, EW, He, Y, Lau, WC, Leung, WK, Mok, MT, Tong, TS, Wong, IC   +6 more
core  

Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention

, 2021
Dominick J. Angiolillo, Mattía Galli
openalex   +2 more sources

Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? [PDF]

, 2014
Al-Khatib, SM, Banerjee, A, Blendea, D, Camm, AJ, Conroy, JM, Cosio, FG, De Bono, J, G Cosio, MD, Guasch, E, Halperin, JL, Hess, PL, Kirchhof, P, Lip, GY, Nattel, S, Ruskin, J, Savelieva, I   +15 more
core   +1 more source

Investigation on Dabigatran Etexilate and Worsening of Renal Function in Patients with Atrial fibrillation: The IDEA Study

, 2019
Mauro Molteni, Matteo Crippa, Annalisa Orenti, Hernan Polo Friz, A. Menghini, Pierluigi Tramacére, Giuseppe Marano, Claudio Cimminiello, Patrizia Boracchi   +8 more
openalex   +2 more sources

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies [PDF]

, 2017
Stephen H. Norris, Steven Ramael, Ippei Ikushima, Wouter Haazen, Akiko Harada, Viktoria Moschetti, Susumu Imazu, Paul Reilly, Benjamin Lang, Joachim Stangier, Stephan Glund   +10 more
openalex   +1 more source

An Experience with Reversal of Dabigatran with Two Doses of Idarucizumab, Hemodialysis, and Time in the Setting of Anuric Renal Failure and Major Gastrointestinal Bleeding

, 2018
Patel Arpan, Cope Jessica, Harris Neil, Zumberg Marc   +3 more
openalex   +1 more source

Association of rs2244613 Polymorphism with Dabigatran Pharmacokinetics and Safety: A Systematic Review and Meta-Analysis [PDF]

, 2022
Haobo Li, Zhu Zhang, Haoyi Weng, Yuting Qiu, Pablo Zubiaur, Yu Zhang, Guohui Fan, Peiran Yang, Anna‐Leena Vuorinen, Xianbo Zuo, Zhenguo Zhai, Chen Wang   +11 more
openalex   +1 more source

Situación actual de los nuevos anticoagulantes orales [PDF]

, 2013
For more than half a century, vitamin K antagonists have defined oral anticoagulant therapy for the long-term management of thrombotic disorders. Despite its clinical efficacy, vitamin-antagonists have multiple, well-known limitations, including numerous
Albarrán Severo, Beatriz, Andujar Troncoso, Giselle, Cidoncha Morcillo, Borja, García Frade, Luis Javier, González Mena, Beatriz   +4 more
core   +1 more source

Effects of uninterrupted dabigatran on the intensity of anticoagulation during atrial fibrillation ablation

, 2021
Takumi Osawa, Hitoshi Mori, Akane Kawai, Daisuke Kawano, Kenta Tsutsui, Yoshifumi Ikeda, Mitsuki Yamaga, Atsushi Sato, Youdou Gatate, Akira Hamabe, Hirotsugu Tabata, Ritsushi Kato, Kazuo Matsumoto   +12 more
openalex   +1 more source